K-numberK243954
Device namePeriCross™ Epicardial Access Kit
ApplicantCirca Scientific, Inc.
Product codeDYB
Device classClass II
Decision dateApr 24, 2025
DecisionSubstantially Equivalent
Regulation870.1340
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The PeriCross™ Epicardial Access Kit is a sterile medical device designed to provide safe access to the epicardial surface of the heart via a subxiphoid approach. It is intended to facilitate electrophysiology studies in adult patients by delivering a 0.018" guidewire to the pericardial space using a tunneler assembly, access device with integrated needle, and coaxial introducer.

Technological characteristics

The PeriCross uses a blunt obturator-equipped tunneler assembly to reach the pericardium, then deploys a specialized access device with deployable tines to retract pericardial tissue and an integrated 21-gauge needle. This differs from the predicate's 17-gauge Touhy needle approach. The subject device uses a smaller 0.018" guidewire (versus predicate's 0.032") and a 5F×18cm coaxial introducer (versus predicate's 13F×40cm deflectable introducer).

Test standards cited

ISO 10993-1 (biocompatibility), ASTM F1980 (shelf-life), ISTA 3A (transit), ISO 11135 (sterilization), and ISO 14155 (clinical study protocol). Mechanical testing covered dimension, tensile, stiffness, breakage, corrosion, insertion, and puncture characteristics.

Substantial equivalence argument

Although the PeriCross differs technologically from the St. Jude Agilis predicate—particularly in its use of pericardial retraction tines and a smaller integrated needle—the reference device (Epi-Ease K233959) demonstrates that pericardial retraction is an acceptable design feature for this application using identical bench testing methods. Both devices share the same intended use (subxiphoid epicardial access for EP studies), the same principles (access via pericardial puncture and guidewire delivery), and the clinical study showed 100% success in achieving guidewire access with acceptable safety (three cardiac perforations, none requiring surgery). Thus, technological differences do not raise new safety or effectiveness questions.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →